 Data indicate endotracheal UVA light catheter therapy reduces SARS-CoV-2 viral load and improves clinical outcomes in mechanically ventilated SARS-CoV-2 patients ENGLEWOOD, CO ACCESSWIRE March 8, 2021 Aytu BioScience, Inc. NASDAQ:AYTU, a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from a first in-human, open label, clinical trial in SARS-CoV-2 patients has been released. The pre-print publication titled Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study concluded that endotracheal UVA light treatment was associated with a significant reduction of SARS-CoV-2 viral load and improvement in WHO clinical severity scores. 